Cargando…
Beyond BRAF: where next for melanoma therapy?
In recent years, melanoma has become a poster-child for the development of oncogene-directed targeted therapies. This approach, which has been exemplified by the development of small-molecule BRAF inhibitors and the BRAF/MEK inhibitor combination for BRAF-mutant melanoma, has brought new hope to pat...
Autores principales: | Fedorenko, I V, Gibney, G T, Sondak, V K, Smalley, K S M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453440/ https://www.ncbi.nlm.nih.gov/pubmed/25180764 http://dx.doi.org/10.1038/bjc.2014.476 |
Ejemplares similares
-
Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009) -
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
por: Paraiso, K H T, et al.
Publicado: (2010) -
Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015) -
Targeting BRAF for patients with melanoma
por: Arkenau, H-T, et al.
Publicado: (2011) -
Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells
por: Fedorenko, Inna V., et al.
Publicado: (2015)